Nalodeine
 | |
| Identifiers | |
|---|---|
| |
| Synonyms | N-Allylnorcodeine |
| CAS Number | 56195-50-7 |
| PubChem (CID) | 5486632 |
| ChemSpider | 4588998 |
| Chemical and physical data | |
| Formula | C20H23NO3 |
| Molar mass | 325.40152 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Nalodeine, also known more commonly as N-allylnorcodeine, is an opioid antagonist (specifically, an antagonist of the μ-opioid receptor) that was never marketed but is of notability in having been the first opioid antagonist to have been discovered.[1][2] It was first reported in 1915, and this was followed by the clinical introduction of nalorphine (N-allylnormorphine) in 1954, naloxone (N-allyloxymorphone) in 1960, and naltrexone (N-methylcyclopropyloxymorphone) in 1963.[2] Nalmefene (6-desoxy-6-methylene-naltrexone), another structurally related opioid antagonist derivative, was also subsequently introduced, in 1996.[3] In animals, nalodeine both reverses morphine- and heroin-induced respiratory depression and acts as a respiratory stimulant in its own right (i.e., when given alone).[4] Similarly to nalorphine, nalodeine has also been found to act as an agonist of the κ-opioid receptor.[5]
See also
References
- ↑ Gavril Pasternak (17 April 2013). The Opiate Receptors. Springer Science & Business Media. pp. 4–. ISBN 978-1-60761-990-1.
- 1 2 Anil Aggrawal. APC Essentials of Forensic Medicine and Toxicology. Avichal Publishing Company. pp. 554–. ISBN 978-81-7739-441-2.
- ↑ Robert M. Julien; Claire D. Advokat; Joseph E. Comaty (8 October 2010). Primer of Drug Action. Worth Publishers. pp. 349–. ISBN 978-1-4292-3343-9.
- ↑ Bentham Science Publishers (April 1995). Current Medicinal Chemistry. Bentham Science Publishers. pp. 423–.
- ↑ Cho N, Hirobe M, Takayanagi I (1985). "Effects of epoxidation on the actions of normorphine, norcodeine, N-allylnormorphine(nalorphine) and N-allylnorcodeine on the electrically stimulated guinea pig ileum" (PDF). Chem. Pharm. Bull. 33 (4): 1681–6. doi:10.1248/cpb.33.1681. PMID 4042244.